Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV
- PMID: 8537258
- DOI: 10.1093/jac/36.1.109
Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV
Abstract
Two hundred and fifty-five isolates of Candida albicans were collected from 93 patients infected with HIV during the course of a clinical trial comparing ketoconazole with itraconazole for the treatment of oropharyngeal or oesophageal candidosis. The susceptibility of the isolates to both drugs was determined by incubating 0.5-2.0 x 10(4) CFU/mL yeast in 0.25-16 mg/L drug in RPMI1640 buffered with MOPS for 24 h at 35 degrees C in 5%CO2 in microtitre trays. Each plate was agitated before reading the optical density. The IC90, IC80 and IC50 were defined as the lowest drug concentration to reduce the optical density to > or = 90%, 80% and 50% of the growth control respectively. IC90S > 0.25 mg/L of ketoconazole and/or itraconazole were found for 42 isolates recovered from 21 patients, 12 of whom had responded to treatment. IC80S > 0.25 mg/L were found for only six of these isolates which had been recovered from three patients, two of whom responded well to treatment. These results indicate that neither the IC90 nor the IC80 are useful in predicting clinical resistance. None of the isolates exhibited IC50 > 0.25 mg/L to either drug which is consistent with the low incidence of resistance reported for these antifungal agents.
Similar articles
-
[Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].Mycoses. 1997;40 Suppl 1:56-63. doi: 10.1111/j.1439-0507.1997.tb00543.x. Mycoses. 1997. PMID: 9417515 German.
-
Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.J Antimicrob Chemother. 1996 Oct;38(4):691-9. doi: 10.1093/jac/38.4.691. J Antimicrob Chemother. 1996. PMID: 8937963 Clinical Trial.
-
In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.Infection. 1994 Mar-Apr;22(2):124-31. doi: 10.1007/BF01739023. Infection. 1994. PMID: 8070926
-
[Antifungal agent resistance of yeasts of clinical significance].Rev Clin Esp. 1995 Oct;195 Suppl 3:56-7. Rev Clin Esp. 1995. PMID: 9441307 Review. Spanish. No abstract available.
-
[Therapy of candidiasis and cryptococcosis in AIDS].Mycoses. 1994;37 Suppl 2:56-63. Mycoses. 1994. PMID: 7609745 Review. German.
Cited by
-
Antifungal susceptibility testing: practical aspects and current challenges.Clin Microbiol Rev. 2001 Oct;14(4):643-58, table of contents. doi: 10.1128/CMR.14.4.643-658.2001. Clin Microbiol Rev. 2001. PMID: 11585779 Free PMC article. Review.
-
Candida albicans serotype analysis by flow cytometry.J Clin Microbiol. 1996 Sep;34(9):2106-12. doi: 10.1128/jcm.34.9.2106-2112.1996. J Clin Microbiol. 1996. PMID: 8862566 Free PMC article.
-
Invasive oesophageal candidiasis: current and developing treatment options.Drugs. 2003;63(10):971-89. doi: 10.2165/00003495-200363100-00004. Drugs. 2003. PMID: 12699400 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical